Skip To Main Content
Kristen Hallam on Muck Rack

Kristen Hallam

Verified
Charlottesville
As seen in: S&P Global, Bloomberg Businessweek, Bloomberg Markets Magazine, Bloomberg News, The Decisive Podcast: Insights and analysis to empower confident decision-making., NDTV, Mint, The Boston Globe, New Zealand Herald, S&P Global Market Intelligence, Bangor Daily News and
Covers:  science, health policy, biotechnology, mergers & acquisitions, health, pharmaceutics
Doesn't Cover: clinical trial initiation, new product launches
Lead content strategist for @economicsrisk at @SPGMarketIntel. @SABEW, @medillschool. RTs not endorsements; opinions my own. bit.ly/2iXoQAk

Get in touch with Kristen

Contact Kristen, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Kristen Hallam’s Biography

Read Full Bio →

I've covered the business healthcare for more than 20 years, starting with the hospital industry in Nashville, Tenn. in 1996. After seven years as a health policy reporter in Washington DC for Modern Helathcare and Bloomberg News, I moved to London with Bloomberg to become an editor on the European healthcare team. While in London, I started a global environment team for Bloomberg focused on news to inform the carbon trading markets. But I was lured back to healthcare, and I've been covering th…

Kristen Hallam’s Journalist Portfolio

Of Mice Not Men: Safer long-term estrogen therapy; extending lifespan in mice

Of Mice Not Men: Safer long-term estrogen therapy; extending lifespan in mice

This is a recurring column on early stage research in animals or other laboratory models that has not yet ent…

View article →
GlaxoSmithKline pursues Silicon Valley-flavored R&D shake-up with 23andMe

GlaxoSmithKline pursues Silicon Valley-flavored R&D shake-up with 23andMe

GlaxoSmithKline PLC, the U.K.'s largest pharmaceutical company, is joining forces with consumer genetics comp…

View article →
Prices, dealmaking likely to overshadow Q2 earnings for drugmakers: analysts

Prices, dealmaking likely to overshadow Q2 earnings for drugmakers: analysts

Drug pricing is back in the spotlight as pharmaceutical companies gear up for second-quarter earnings, which …

View article →
GSK's chief strategy officer discusses M&A, pharma focus, US tax reform

GSK's chief strategy officer discusses M&A, pharma focus, US tax reform

David Redfern has been chief strategy officer at Brentford, London-based GlaxoSmithKline plc for the last dec…

View article →
2018 healthcare IPO proceeds close to exceeding amounts raised in 2017

2018 healthcare IPO proceeds close to exceeding amounts raised in 2017

Aggregate gross proceeds from global healthcare IPOs so far in 2018 are close to exceeding amounts raised in …

View article →

Articles

Entasis CEO urges reimbursement reform for new weapons against superbugs

|
By Kristen Hallam Verified
| S&P Global Market Intelligence Verified
Entasis Therapeutics President and CEO Manos Perros Source: Entasis Therapeutics Holdings Inc. ➤ Entasis Therapeutics Holdings Inc., which was spun out from AstraZeneca PLC six years ago, has a pipeline of treatments for drug-resistant infections. ➤ The publicly traded U.S. company and its Chinese partner, Zai Lab Ltd., expect to have late-stage study results for antibiotic medicine sulbactam/durlobactam, or SUL-DUR, this year.
Open in Who Shared Issue with article?

COVID-19 Impact & Recovery: Healthcare Outlook for H2 2021

|
By Kristen Hallam Verified
| S&P Global Verified
What are the key themes to shape the healthcare sector in the second half of 2021 and beyond? 1: The ongoing pandemic The healthcare industry was both deeply impacted by COVID-19 and tasked with mounting an effective response to it. As a consequence, probability of default scores fell for all segments of healthcare in Q1 2021 compared with their highs in 2020.
Open in Who Shared Issue with article?

Most hospitals in US value-based purchasing program will see higher payments

|
By Kristen Hallam Verified
| S&P Global Verified
The majority of the hospitals participating in a U.S. government-run, value-based purchasing program will receive higher Medicare payments in fiscal 2019, according to the Centers for Medicare and Medicaid Services. More than 55% of the 2,800 hospitals in the program, which rewards quality care, will enjoy higher reimbursements for inpatient stays, CMS said Dec. 3. Created through the Affordable Care Act, the program is in its seventh year.
Open in Who Shared Issue with article?
See all 158 licensed articles (162 Total)